Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Anderson, Caleb F.; Grimmett, Maria E.; Domalewski, Christopher J.; Cui, Honggang

doi:10.1002/wnan.1586

Cited by 74 publications

(67 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the nonnegligible safety concerns caused by their low systemic toxicities, this method remains a promising approach to target lung cancer cells during the targeted therapy process [178]. It has been indicated that nanomedicine inhalation can also be used to treat lung cancer [179]. One study found that siRNA combined with PTX inhalation via nanostructured lipid carriers can significantly decrease lung tumor volumes [180].…”

Section: Resultsmentioning

confidence: 99%

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

Lai

Tang

et al. 2020

IJMS

View full text Add to dashboard Cite

Lung cancer is one of the most malignant cancers around the world, with high morbidity and mortality. Metastasis is the leading cause of lung cancer deaths and treatment failure. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs), two groups of small non-coding RNAs (nc-RNAs), are confirmed to be lung cancer oncogenes or suppressors. Transforming growth factor-β (TGF-β) critically regulates lung cancer metastasis. In this review, we summarize the dual roles of miRNAs and lncRNAs in TGF-β signaling-regulated lung cancer epithelial-mesenchymal transition (EMT), invasion, migration, stemness, and metastasis. In addition, lncRNAs, competing endogenous RNAs (ceRNAs), and circular RNAs (circRNAs) can act as miRNA sponges to suppress miRNAs, thereby mediating TGF-β signaling-regulated lung cancer invasion, migration, and metastasis. Through this review, we hope to cast light on the regulatory mechanisms of miRNAs and lncRNAs in TGF-β signaling-regulated lung cancer metastasis and provide new insights for lung cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

Lai

Tang

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Once reaching the alveolar region, microparticles are expected to readily dissolve, delivering the nanocarriers which, in turn, are internalized by AMs and can release the encapsulated drug. [40,51,77,78] Some recent approaches applying passively targeted nanocar-riers for pulmonary administration route are summarized in Table 2.…”

Section: Passive Targetingmentioning

confidence: 99%

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Baranyai

Soria‐Carrera

Alleva

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

The appearance and rapid spread of drug resistant strains of tuberculosis (TB), one of the deadliest infectious diseases, pose a serious threat to public health and increase the need for shorter, less toxic, and more effective therapies. Developing new drugs is difficult and often associated with side effects, so nanotechnology has emerged as a tool to improve current treatments and to rescue drugs having elevated toxicity or poor solubility. Due to their size and surface chemistry, antimicrobial‐loaded nanocarriers are avidly taken up by macrophages, the main cells hosting Mycobacterium tuberculosis. Macrophages are continuously recruited to infected areas, they can transport drugs with them, making passive targeting a good strategy for TB treatment. Active targeting (decorating surface of nanocarriers with ligands specific to receptors displayed by macrophages) further increases local drug concentration, and thus treatment efficacy. Although in in vivo studies, nanocarriers are often administered intravenously in order to avoid inaccurate dosage in animals, translation to humans requires more convenient routes like pulmonary or oral administration. This report highlights the importance and progress of pulmonary administration, passive and active targeting strategies toward bacteria reservoirs to overcome the challenges in TB treatment.

show abstract

“…They can thus also restrict drug exposure to healthy cells. However, they were also associated with certain loopholes such as bolus drug release culminating into severe lung toxicity, short residence time, and poor aqueous solubility [10]. The other contemporary TB treatment includes oral and parenteral dosage forms.…”

Section: Nanotechnological Approach For Combating Tbmentioning

confidence: 99%

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Nabi

Rehman

Aggarwal

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Tuberculosis (TB) classified as one of the most fatal contagious diseases is of prime concern globally. Mycobacterium tuberculosis is the causative agent that ingresses within the host cells. The approved conventional regimen, though the only viable option available, is unfavorably impacting the quality of life of the affected individual. Despite newer antibiotics gaining light, there is an unending demand for more therapeutic alternatives. Therefore, substantial continuous endeavors are been undertaken to come up with novel strategies to curb the disease, the stepping stone being nanotechnology. This approach is instrumental in overcoming the anomalies associated with conventional therapy owing to their intriguing attributes and leads to optimization of the therapeutic effect to a certain extent. This review focusses on the different types of nanocarrier systems that are being currently explored by the researchers for the delivery of anti-tubercular drugs, the outcomes achieved by them, and their prospects.

show abstract

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Cited by 74 publications

References 199 publications

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

MiRNAs and LncRNAs: Dual Roles in TGF-β Signaling-Regulated Metastasis in Lung Cancer

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention

Contact Info

Product

Resources

About